Novavax
The present study aims to investigate the safety and immunogenicity of the Novavax JN.1 subvariant vaccine SARS-CoV-2 rS adjuvanted with Matrix-M (NVX CoV2705) in previously vaccinated adults. A descriptive comparison will be made with participants who received the prior authorized vaccine NVX-CoV2601 in an earlier study (2019nCoV-313).
Severe Acute Respiratory Syndrome Coronavirus 2 Infection
NVX-CoV2705 Vaccine
PHASE3
This is a Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of a JN.1 subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ (NVX CoV2705) in previously vaccinated adults. Approximately 60 participants will be enrolled to receive a single dose of NVX CoV2705 on Day 0 and remain on study for immunogenicity until Day 28 and safety data collection up to 180 days post-vaccination.
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 60 participants |
Masking : | NONE |
Primary Purpose : | PREVENTION |
Official Title : | A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine |
Actual Study Start Date : | 2024-10-14 |
Estimated Primary Completion Date : | 2024-12-10 |
Estimated Study Completion Date : | 2025-06-20 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years to 90 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: | 1 |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Foothills Research Center - CCT Research
Phoenix, arizona, United States, 85044
Not yet recruiting
Benchmark Research
Austin, Texas, United States, 78705